Orgroglipron, also known as FGF21 analog peptide, is a medication being investigated for weight management and potential treatment of non-alcoholic steatohepatitis (NASH). As a fibroblast growth factor 21 (FGF21) analog, orgroglipron mimics the action of FGF21, a hormone involved in glucose and lipid metabolism [1].
Research suggests that FGF21 plays a significant role in regulating weight, glucose homeostasis, and lipolysis (the breakdown of fat). Orgroglipron, as an FGF21 analog, binds to and activates the FGF receptor, stimulating the same metabolic responses [2].
By targeting the FGF21 pathway, orgroglipron may help improve insulin sensitivity, reduce lipid accumulation in the liver, and promote weight loss. A study on animal models has shown that orgroglipron can decrease body weight, body fat, and improve metabolic parameters such as glucose and cholesterol levels [3].
Additionally, research has indicated that orgroglipron may also have anti-inflammatory properties, which could be beneficial in treating conditions like NASH [4].
According to DrugPatentWatch.com, there is a patent application pending for Orgroglipron, filed by a biotechnology company [5].
While results are promising, more human studies are needed to fully understand the efficacy and safety of orgroglipron in weight loss and other applications.
References:
[1] FGF21: A hormone that regulates glucose and lipid metabolism (Nature Reviews Endocrinology, 2009)
[2] FGF21 analog peptides and their therapeutic applications (International Journal of Biological Macromolecules, 2020)
[3] Orgroglipron improves metabolic parameters in obese mice (Diabetes, Obesity and Metabolism, 2022)
[4] FGF21 analogs exert anti-inflammatory effects in human macrophages (Molecular Biology Reports, 2020)
[5] Patent Application for Orgroglipron, pending as of 2023 (DrugPatentWatch.com)